Categories
Banking and Restructuring Controlled Substance Act Regulatory Compliance

Blazing New Ground: Cannabis Holding Company Obtains Chapter 15 Recognition

Scott H. Moskol, Evan Jason Zucker, and Michael B. Schaedle 

Introduction

The cannabis industry has been undergoing a significant wave of defaults and receivership proceedings in recent years. Faced with price compression and increased competition including from the illicit market, limited access to traditional sources of debt and capital markets, and compressed margins, many cannabis companies have found themselves unable to service their debt obligations. The Cannabist Company Holdings Inc.’s (“CCHI”) restructuring is emblematic of these broader industry challenges and provides a potential new roadmap for other cannabis enterprises navigating similar financial distress.

On May 9, 2026, the United States Bankruptcy Court for the District of Delaware entered an order granting recognition of the Canadian insolvency proceeding of CCHI and The Cannabist Company Holdings (Canada) Inc. (collectively, the “Debtors”) as a foreign main proceeding under Chapter 15 of the Bankruptcy Code. This decision is the first time a U.S. bankruptcy court has recognized a foreign insolvency proceeding involving a cannabis-related business under Chapter 15, notwithstanding the continued federal prohibition of adult use cannabis under the Controlled Substances Act (“CSA”). Importantly, the entities that obtained recognition are not the “plant-touching” cannabis operating companies. The subsidiaries that hold state licenses and directly produce, sell, and handle cannabis are not debtors in either the Canadian proceeding or the Chapter 15 cases.

This recognition, coupled with the recent rescheduling of medical cannabis from a Schedule I to a Schedule III controlled substance under the CSA, marks a significant shift in the federal posture toward the cannabis industry. Together, these developments open the door to new forms of relief under the Bankruptcy Code for cannabis-related businesses, which have historically been denied access to federal bankruptcy protection.

Background: The Cannabist Company and Its Restructuring

The multi-state operator (“MSO”), CCHI is a Canadian holding company publicly traded on the Cboe Canada Inc. stock exchange, and the ultimate parent of non-debtor subsidiaries that operate a vertically integrated cannabis cultivation, manufacturing, and retail business in eight U.S. states where medical or adult-use cannabis is legal under state law. The debtors, along with their non-debtor’s subsidiaries (the “CC Group”) have a capital structure that included approximately $220 million in funded debt, primarily consisting of approximately $179 million in senior secured notes issued under a Canadian-law-governed indenture. The CC Group incurred net losses of $105.1 million for the 12 months ended December 31, 2024, and $124.2 million in net losses for the nine months ended September 30, 2025.

Following a default on the Senior Notes in January 2026, the CC Group entered into a forbearance agreement with a majority of senior noteholders and subsequently commenced a Companies’ Creditors Arrangement Act (“CCAA”) proceeding in the Ontario Superior Court of Justice (Commercial List) on March 24, 2026. On March 25, 2026, CCHI, acting as the duly appointed foreign representative, filed Chapter 15 petitions in Delaware, seeking recognition of the Canadian proceeding and enforcement of the Canadian court’s initial order.

Read the full client alert on our website.

Categories
Banking and Restructuring Controlled Substance Act Legislation Regulatory Compliance

DOJ Final Order Rescheduling Marijuana: Key Implications, Guidance, and Opportunities for State-Licensed Medical Cannabis Businesses

Frank A. SegallScott H. Moskol, and Shane A. Pennington 

On April 23, 2026, the U.S. Department of Justice (“DOJ”) reached a historic milestone in federal cannabis policy when Acting Attorney General Todd Blanche signed a final order transferring Food & Drug Administration (“FDA”)-approved marijuana products and all cannabis subject to a state medical marijuana license from Schedule I to Schedule III of the Controlled Substances Act (“CSA”).

For patients, providers, operators, lenders, investors, and virtually everyone involved in this industry, this marks one of the most significant federal cannabis developments in decades. The order takes effect immediately and creates a new pathway for state-regulated medical marijuana businesses to operate in compliance with both state law and federal controlled substances law for the first time in history. 

Although the order does not currently address recreational cannabis, its impact on the industry is significant. Blank Rome is committed to guiding clients through these policy changes and helping them leverage emerging opportunities in the sector, which we believe will further benefit the industry as a whole. Here are the significant highlights and impacts of the policy change. 

Categories
Banking and Restructuring Controlled Substance Act Legislation Meet Blank Rome Regulatory Compliance

President Trump Officials Reclassify Marijuana in Historic Announcement

Frank A. Segall —

A statement from Frank A. Segall, Chair of Blank Rome’s Cannabis Industry Group:

The Trump Administration’s move on the rescheduling of cannabis is long overdue and monumental. It recognizes the importance of further legitimizing the health and wellness benefits of this miracle plant, allowing research and clinical trials to advance, and expanding access for those who may benefit from its medicinal properties.

However, meaningful and equitable access for all Americans, and fair treatment of the industry comparable to that extended to all other businesses, will only be achieved with full rescheduling of cannabis.

Blank Rome’s Cannabis Industry Group has been at the forefront of the cannabis industry for almost 15 years, successfully and innovatively helping its clients navigate the regulatory complexities that have long challenged cannabis businesses. This order moves us in the right direction, but it does not get us there entirely. 

Blank Rome is committed to assisting its clients and the cannabis industry in navigating through this order, addressing its complexities, and continuing to advocate for full rescheduling.

Categories
Banking and Restructuring Controlled Substance Act Interviews Legislation Regulatory Compliance

What Cannabis Lenders Think Rescheduling Will Mean for Capital Markets

Gustav Stickley V —

The prospect of federal rescheduling of cannabis has the lending community buzzing. We recently sat down with Alex Mazza, Director of Underwriting at Chicago Atlantic Group, as well as Michelle Haughton and Bobby Boyda of Needham Bank, to get their take on what rescheduling could mean for borrowers, lenders, and the broader capital markets.

Stronger Borrowers, Bigger Demand

One of the most immediate effects lenders anticipate is a meaningful improvement in borrower credit profiles, particularly for operators with retail operations. With the burden of Section 280E potentially lifting, operators should see more available cash on their balance sheets, thus deepening the pool of eligible borrowers. Mazza emphasized that this will drive increased demand for capital—but crucially, not an immediate increase in capital supply. In his view, new lenders are unlikely to rush into the industry given cannabis’ continued federal illegality and the robust internal processes required to set up a cannabis lending program.

Categories
Banking and Restructuring Controlled Substance Act Legislation Mergers and Acquisitions Regulatory Compliance

Distressed Cannabis Sale-Leaseback Companies: What Investors and Operators Need to Know

Marc A. Polito —

The cannabis industry has experienced dramatic highs and lows over the past several years. While legalization efforts have expanded markets across the United States, many cannabis companies have found themselves in severe financial distress, burdened by high operating costs, regulatory complexity, and limited access to traditional financing. One area that has drawn particular attention is the sale-leaseback model—a once-promising financing structure that has become a source of significant stress for both operators and the real estate companies and equipment lessors that serve them. Here’s a breakdown of the top four things to know about the use of sale-leasebacks in the cannabis industry.

1. Understanding the Real Estate Sale-Leaseback Model in Cannabis

A sale-leaseback transaction involves a cannabis operator selling its real property—such as a cultivation facility or dispensary location—to a third party or affiliate real estate investment company, then leasing that same property back under a long-term lease agreement. For the operator, this arrangement frees up capital that would otherwise be locked in real estate, providing much-needed liquidity to fund operations, expansion, or debt repayment. For the buyer, typically a real estate investment trust or similar entity, the arrangement provides a steady stream of rental income backed by a tangible asset.

This model gained traction in the cannabis space largely because of federal illegality under the Controlled Substances Act, which left cannabis companies cut off from conventional bank lending and capital markets.

Sale-leasebacks offered a creative workaround, enabling operators to monetize their real estate holdings without relying on traditional debt instruments.

2. Equipment Sale-Leasebacks: A Parallel Structure

While real estate sale-leasebacks have received much of the attention, equipment sale-leasebacks have played an equally important role in cannabis financing. Under this structure, a cannabis operator sells specialized equipment—such as extraction machines, HVAC systems, lighting arrays, or processing machinery—to a third party or affiliate financing company, then leases that equipment back for continued use. Like its real estate counterpart, the equipment sale-leaseback provides operators with immediate liquidity while allowing them to retain operational use of critical assets.

However, equipment sale-leasebacks carry their own distinct risks. Cannabis equipment is often highly specialized, meaning its residual value outside the cannabis industry can be minimal. If an operator defaults on its lease payments, the financing company may be left holding equipment that is difficult to redeploy or resell at a reasonable price. Additionally, equipment depreciates far more rapidly than real estate, which can create a mismatch between the outstanding lease obligations and the declining value of the underlying asset. These dynamics have left many equipment leaseback companies in a precarious financial position as operator defaults have increased across the industry.

3. Why Distress Has Emerged

Despite initial optimism, several factors have converged to place sale-leaseback companies under significant financial pressure.

  • First, cannabis commodity prices have declined sharply in many mature markets, driven by oversupply and aggressive competition. As operator revenues have fallen, many lessees have struggled to meet their lease obligations, leading to rising delinquencies and defaults across both real estate and equipment leases.
  • Second, the real estate and equipment financing companies themselves often underwrote these transactions based on optimistic projections about the cannabis market’s growth trajectory. When those projections failed to materialize, the underlying economics of many deals became unsustainable. For example, real estate properties that are acquired at premium valuations tied to cannabis use can be difficult to repurpose for other commercial uses whether due to current outfitting of the location or as a result of local zoning laws, and specialized equipment can hold even less residual value outside the cannabis industry, leaving both landlord and lessors with impaired assets and limited options.
  • Third, the broader macroeconomic environment has compounded these challenges. Rising interest rates have increased the cost of capital for real estate companies and equipment lessors, while simultaneously depressing asset valuations. For sale-leaseback companies that relied on leverage to fund acquisitions of real estate and equipment, this has created a painful squeeze on balance sheets. What we have seen is a trend toward sale-leaseback companies defaulting under their own debt obligations used to finance the acquisition of real estate and equipment due to their underlying portfolio tenants and lessees defaulting under respective lease agreements.

4. Implications for Stakeholders and Operators

For cannabis operators, the distress of their sale-leaseback landlords can create its own set of complications. A landlord in financial difficulty may be unable to fund required maintenance or capital improvements under the leases, and as a result, may seek to renegotiate lease terms, or may face foreclosure proceedings that introduce uncertainty into the operator’s occupancy rights.

For investors and creditors of sale-leaseback companies, the path forward often involves difficult decisions around restructuring, asset disposition, or recapitalization. In some cases, distressed sale-leaseback portfolios have attracted opportunistic buyers looking to acquire cannabis-linked real estate at a discount.

The distressed cannabis sale-leaseback space serves as a cautionary tale about the risks of sector-specific financing models built on speculative market assumptions. As the industry continues to mature, stakeholders would be well served by approaching these structures with clear-eyed diligence and realistic expectations about the market’s trajectory.

Categories
Banking and Restructuring Controlled Substance Act Interviews Legislation Meet Blank Rome Mergers and Acquisitions Regulatory Compliance

Cannabis Rescheduling: Will the Vault for Cannabis Banking and Financial Services Finally Be Opened?

Scott H. Moskol and Lauren Medeiros Forster —

Whether you are a cannabis operator, lender, or investor, you have probably been hearing a lot of buzz about the potential rescheduling of cannabis from Schedule I to Schedule III under the federal Controlled Substances Act, especially following President Trump’s recent executive order directing federal agencies to initiate the process of rescheduling marijuana and reviewing related regulations. It is an exciting development, and there is plenty of reason for optimism, but let’s take a look at what this shift could change (and likely not change) when it comes to banking, lending, and financial services in cannabis.

  1. The Banking Landscape: Evolution, Not Revolution

It is likely that rescheduling cannabis to Schedule III will not dramatically change what banks are presently required to do under the Bank Secrecy Act (the “BSA”) and the 2014  FinCEN guidance on banking marijuana-related businesses. These BSA-related compliance obligations (i.e., the enhanced due diligence, suspicious activity reporting, and monitoring requirements) will not vanish as a result of rescheduling. Banks will still need to navigate a complex regulatory and compliance environment, and if you are a financial institution already working with cannabis operators or you are a cannabis business already working with a financial institution, your day-to-day relationship will not change.

What the industry is hoping for, however, is that rescheduling will prompt federal regulators to issue amended or entirely new guidance on how banks can engage with the cannabis industry. That kind of updated regulatory framework could open doors to more streamlined processes and potentially reduce some of the friction that has defined cannabis banking for years but more importantly bring in new financial institutions providing banking and lending services to the industry. Eyes should be kept on Treasury and the banking regulators—their next moves will matter once cannabis is rescheduled.

Categories
Banking and Restructuring Controlled Substance Act Employment Issues ESOPs (Employee Stock Ownership Plans) Legislation Mergers and Acquisitions Regulatory Compliance

High Stakes and Material Changes in the Bay State: Senate Bill No. 2722 vs. House Bill No. 4160

Lauren Medeiros Forster —

There were several material changes relating to strategy, compliance, and deal‑making advanced by Massachusetts Senate Bill No. 2722 (“S. 2722”) on November 13, 2025. Below is a short summary of what you need to know about the Senate’s rewrite and meaningful reshaping of several House‑backed ideas (under House Bill No. 4160 (“H. 4160”)) for changing the legal regime of cannabis in the Commonwealth.

1.      Employee Stock Ownership Plans

Employee stock ownership plans (“ESOPs”) are here to stay. Both bills tell the Massachusetts Cannabis Control Commission (“CCC”) to set up clear procedures to allow the sale of a business to employees via an ESOP and to exclude a trustee acting solely for an ESOP during or after a sale when counting toward cannabis license caps under the Massachusetts cannabis laws. That part did not change, which is a positive result for the Commonwealth. The proposed changes to the current law enable succession planning, retention, and worker‑ownership options for operators and investors without tripping license caps and also improve exit/liquidity paths for owners. This also means there would be no caps on the number of licenses an ESOP can own.

Categories
Banking and Restructuring Controlled Substance Act Interviews Legislation Meet Blank Rome Mergers and Acquisitions Regulatory Compliance

Closing the Hemp Loophole: What Monday’s Farm Bill Update Means for Delta-8 and Hemp-Derived THC

Marc A. Polito —

At Blank Rome’s 9th Annual State of the Cannabis Industry Conference, Frank A. Segall, partner and co-chair of the firm’s Cannabis practice, asked a panel—including Joseph Andreae, CEO of CULTA, Jared Maloof, CEO of Standard Wellness, Ed Schmults, CEO of Firelands Scientific, and Jim Scott, CEO of Statehouse Holdings—what is the number one issue confronting the cannabis industry today? All four chief executives unanimously echoed the same sentiment: the number one issue confronting state-regulated cannabis operators today is the unregulated hemp market, which has become a growing thorn in their sides as the hemp market picked up steam over the past few years. Well, with new action by lawmakers yesterday, it appears this issue is on the brink of being resolved!

Over the past six years, the hemp industry has transformed from a niche agricultural sector into a national marketplace for diverse cannabinoid products. That transformation was catalyzed by the 2018 Farm Bill, which legalized hemp by defining it as cannabis with no more than 0.3 percent delta-9 tetrahydrocannabinol (“THC”) on a dry-weight basis. What resulted from this was an unintended market: intoxicating hemp-derived cannabinoids such as delta-8 THC, delta-10 THC, and other analogs produced from cannabidiol (“CBD”) isolates through chemical conversion. The “hemp loophole,” as it came to be known, allowed psychoactive products to proliferate in convenience stores, restaurants, and online and circumvented the strict controls applied to state-licensed cannabis.

Categories
Banking and Restructuring

The Cannabis Industry’s $6 Billion Debt Wall

Gustav Stickley V —

A debt avalanche is bearing down on the U.S. cannabis market to the tune of roughly six billion dollars coming due by the end of 2026, with the top five borrowers—each a multi-state operator (“MSO”)—accounting for about $3.4 billion. The sector’s reliance on costly debt, born of limited access to traditional capital, has set the stage for a potentially messy, uneven reckoning.

Why this matters now

  • Scale and timing: The maturities bunch up into 2026, compressing the refinancing window and elevating risk across the ecosystem.
  • Cash flow stress: Many capital structures are expensive, and several operators still burn cash, curbing their ability to refinance on favorable terms.
  • Market significance: Despite headwinds, cannabis generated $32 billion in 2024 revenue, employed 400,000+ people, and contributed $4.4 billion in state taxes—meaning outcomes here have real economic spillovers.
Categories
Banking and Restructuring Controlled Substance Act Employment Issues Legislation Meet Blank Rome Mergers and Acquisitions Regulatory Compliance

Turning Over a New Leaf: How Cannabis Receiverships Can Cultivate a Stronger Future

Lauren Medeiros Forster —

It is no secret that the cannabis industry has been on a wild ride lately, especially in mature markets. Many operators are feeling the pressure, and they are not alone. Let us break down the current landscape, why it is tough out there, and how receiverships and distressed sales might actually be a positive move for struggling cannabis companies.

Many developed cannabis markets are facing serious challenges. Inflation and a shaky economy are making it harder for businesses to stay afloat (regardless of industry type), on top of market saturation that has caused cannabis prices to drop, and tight profit margins for businesses in the more established marijuana states. This is compounded with the harsh effects of tax burdens due to 280E—where cannabis companies are unable to deduct otherwise established business expenses from gross income as a result of the federal illegality of cannabis in the United States—and lack of liquidity from inability to access traditional debt financing and institutional equity markets. As a result, many cannabis companies are finding it difficult to pay their debts and keep the lights on. And because cannabis is still federally illegal in the United States, struggling cannabis operators are limited when it comes to utilizing federal bankruptcy mechanisms for relief.

But hope is not lost. Even in tough times, cannabis businesses along with their management, creditors, and investors, have found options to help their companies restructure and move forward. One of those is a state-level receivership.